NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Pharmacokinetics and Safety of RV521 Formulations

CompletedPhase 1

Sponsor: Pfizer

Conditions: Respiratory Syncytial Virus Infections

Interventions: RV521

Countries: United Kingdom

The main aims of the study are to assess the pharmacokinetics and safety of single doses of RV521 administered as two different formulations

Eligibility overview

Sex: ALL

Age: 18 Years to 45 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Willing to comply with protocol defined contraception requirements
* In good health with no history of major medical conditions
* A body mass index (BMI) of 18-25 kg/m\^2, inclusive

Exclusion Criteria:

* Evidence of any clinically significant or currently active major medical condition
* Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening
* Not willing to comply with protocol defined restrictions for intake of drugs of abuse, alcohol, nicotine-containing products, medication (prescription, OTC, herbal, vitamins/minerals etc) and specified food and drink products

Locations (1)

London, United Kingdom